Scandinavian Biopharma signs a joint procurement with EU commission to supply diphtheria antitoxin
Scandinavian Biopharma and The European Commission’s Health Emergency Preparedness and Response Authority (HERA) has signed a joint procurement framework contract for the supply of diphtheria antitoxin. Eight Member States are participating in the agreement, under which they can purchase 1600 vials of diphtheria antitoxin.
Diphtheria is a serious disease and vaccination is the only effective method of preventing the disease. Achieving and sustaining high vaccination coverage in the population is critical for preventing diphtheria from causing serious or fatal illness. Even though diphtheria is a rare disease in the EU cases of diphtheria continues to be diagnosed.
For successful treatment rapid administration of diphtheria antitoxin is required. This joint procurement will facilitate access to diphtheria antitoxin for the Member States and will ensure that those who need treatment are able to access it in a timely manner.
Björn Sjöstrand, CEO of Scandinavian Biopharma, said: “HERA is a key pillar of the European Health Union and a fundamental asset to strengthen the EU’s health emergency response and preparedness. We are very proud to be a strategic partner to HERA. By building a robust infrastructure across EU nations we are supporting the preparedness across the region and make it possible to faster respond to potential future diphtheria outbreaks.”
https://ec.europa.eu/commission/presscorner/detail/en/mex_24_4164
